{"id":20381,"date":"2012-10-01T12:09:52","date_gmt":"2012-10-01T12:09:52","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=20381"},"modified":"2012-10-05T16:52:17","modified_gmt":"2012-10-05T16:52:17","slug":"study-summaries-from-icaac-2012","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/20381","title":{"rendered":"Study summaries from ICAAC 2012"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/strong><\/p>\n

The following brief summaries on new drugs and treatment strategies include links to the ICAAC online abstracts and\/or links to slidesets or articles posted at natap.org.<\/strong><\/p>\n

Dolutegravir results superior to efavirenz at week 48 in treatment-naive patients<\/h2>\n

The top-line results from the randomised, double-blinded, placebo-controlled, non-inferiority, Phase 3 SPRING study were released in July just prior to the IAS conference.<\/p>\n

Dolutegravir (50 mg once-daily) was paired with abacavir\/3TC and compared to efavirenz\/tenofovir\/FTC (Atripla) in 674 treatment-naive patients, generally in early stage infection.<\/p>\n

At week 48, the dolutegravir arm showed superiority with 88% vs 81% of patients suppresed to <50 copies\/mL (difference +7.4%; 95%CI: +2.5, +12.3; p=0.003).<\/p>\n

This result was driven by fewer discontinuations due to toxicity in the dolutegravir arm (2% vs 10%). Virological failure occured in 4% of patients in each group.<\/p>\n

Ref: Walmsley S et al. Dolutegravir (DTG; S\/GSK1349572) + abacavir\/lamivudine once daily statistically superior to tenofovir\/emtricitabine\/efavirenz: 48-week results – SINGLE (ING114467). 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H-556b.<\/p>\n

http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=e1c18d5b-830f-4b4e-8671-35bcfb20eed5&cKey=af219b7d-2171-46b2-91ef-b8049552c9e5&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d<\/a><\/p>\n

http:\/\/www.natap.org\/2012\/ICAAC\/ICAAC_06.htm<\/a><\/p>\n

Elvitegravir\/cobicistat has no clinically significant interactions with methadone or buprenorphine<\/h2>\n

Results from two small PK studies in patients on stable opiate substitution therapy (n=12 methadone; n=18 buprenorphine) reported no indications of an interaction between elvitegravir\/cobicistat and methadone and only modestly increased buprenorphine levels that did not require dose modification.<\/p>\n

Ref: Bruce RD et al. Pharmacokinetics of cobicistat-boosted elvitegravir administered in combination with methadone or buprenorphine\/naloxone. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract A-1250.<\/p>\n

http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=a96a704b-ee24-44df-8955-f1688acf7663&cKey=7c849c73-6efd-4fce-9e2c-218df03ff40c&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d<\/a><\/p>\n

http:\/\/www.natap.org\/2012\/ICAAC\/ICAAC_40.htm<\/a><\/p>\n

Albuvirtide: long-acting formulation T-20<\/h2>\n

The first in vivo<\/em> virological data were presented for a new long-acting formulation of the fusion inhibitor T-20. This compound is in development with the Chinese company Chongquing Biotechnologies.<\/p>\n

The limited information from the abstract reported results from a dose-finding study in Chinese HIV positive patients who received single IV injections daily for three days, followed by once-weekly injections for a further two weeks.<\/p>\n

Mean maximum declines of 0.68 and 1.05 log copies\/mL were reported with 160 mg and 320 mg doses respectively. In a single-dose study, viral reduction was maintained for 6-10 days, with albuvirtide showing a plasma half-life of 10-13 days.<\/p>\n

Ref: Wu H et al. Albuvirtide, the first long-acting HIV fusion inhibitor, suppressed viral replication in HIV-infected adults. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H554.<\/p>\n

http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=e1c18d5b-830f-4b4e-8671-35bcfb20eed5&cKey=70d14bcc-bad6-4754-b4b1-66b7d2559a23&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d<\/a><\/p>\n

http:\/\/www.natap.org\/2012\/ICAAC\/ICAAC_27.htm<\/a><\/p>\n

High rates of adherence and virological suppression with once-daily raltegravir and directly observed therapy (DOT) in IDU patients<\/h2>\n

Although results of once-daily raltegravir studies did not support a label change or further research into this dosing option, a Canadian study reported very high rates of success in a cohort of 121 HIV positive treatment experienced injecting drug users (n=103 male) that also included comprehensive adherence support. DOT ws used by 81% of patients.<\/p>\n

Over a median follow-up of 12 (6-18) months, 80% of the cohort achieved or maintained virologic suppression to <50 copies\/mL (appromiately half the group switched with undetectable viral load at baseline.<\/p>\n

Importantly, CD4 counts increased by a median 80 cells\/mm3 from a median of\u00a0 425 cells\/mm3 (range 20-1600) at baseline. Adherence exceeded 90%. Virologic rebound to >400 copies\/mL occurred in 10% of patients but resuppression was achieved in all cases over the subsequent three months. There were no cases of emergent raltegravir resistance.<\/p>\n

Ref: Stewart K et al. Safety and efficacy of once daily raltegravir to enhance adherence and efficacy of HAART in vulnerable HIV-infected patients. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H-884.<\/p>\n

http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=e47a6478-452a-4c7c-9ebc-86a50a648cc7&cKey=8eb48052-2257-4337-8e1d-51658c50fefe&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d<\/a><\/p>\n

http:\/\/www.natap.org\/2012\/ICAAC\/ICAAC_21.htm<\/a><\/p>\n

Role of HIV DNA, recent cellular infection and poor immunological responses despite viral suppression<\/h2>\n

A group of French researchers looking at immunological non-responders despite viral suppression <50 copies\/mL reported an association with HIV DNA as a marker of recent cellular infection and ongoing replication and overexpression of the activation marker CD38+, that was higher in patients with reduced CD4 responses on treatment. The natap report linked below report this study in detail.<\/p>\n

Ref: Psomas KC et al. Poor CD4+ T-cell restoration linked to residual HIV-1 reverse transcription under antiretroviral therapy. 52nd ICAAC, 9-12 September 2012, San Francisco. Abstract H-1570a.<\/p>\n

http:\/\/www.abstractsonline.com\/Plan\/ViewAbstract.aspx?sKey=0bc31dda-3bfe-443f-8051-1788529cb053&cKey=e7b3f725-db08-4db9-953e-126811e32026&mKey=%7b6B114A1D-85A4-4054-A83B-04D8B9B8749F%7d<\/a><\/p>\n

http:\/\/www.natap.org\/2012\/ICAAC\/ICAAC_35.htm<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base The following brief summaries on new drugs and treatment strategies include links to the ICAAC online abstracts and\/or links to slidesets or articles posted at natap.org. Dolutegravir results superior to efavirenz at week 48 in treatment-naive …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3,15],"tags":[165],"class_list":["post-20381","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","category-basic-science-and-immunology","tag-icaac-52nd-2012"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=20381"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/20381\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=20381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=20381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=20381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}